Gritstone bio Announces Appointment of Stephen Webster to its Board of Directors forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.
ENGLEWOOD, Colo., Feb. 10, 2022 Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for prevalent inflammatory conditions, today announced the appointment of Elizabeth Varki Jobes, Esq.
Share this article
Share this article
ResearchAndMarkets.com s offering.
The global opioid induced constipation drugs market is rising at a significant pace, projected to rise at a CAGR of 4.7% during the estimated period from 2020 to 2028, starting from US$ 2,656.4 Mn in 2019.
The mechanism of action of opioid analgesics through binding to the mu, delta, and kappa receptors present in the brain by crossing the blood-brain barrier and giving the desired analgesic effect to treat non-cancer pain. In addition, the opioids bind to the mu receptors present in the gastrointestinal tract, which result in a contraction of the smooth muscles and alter the peristaltic movement causing constipation. Usually, the patients opt for over the counter osmotic laxatives and stimulant cathartics, which have been beneficial in providing relief from constipation in patients taking opioid analgesics for 3-4 weeks. In patients seeking palliative care, doctors prescribe mu-receptor antagonists and pro
Gain Therapeutics
Gain Therapeutics Strengthens Leadership Team with the Appointment of Four Industry Leaders to Its Board of Directors
Gain Therapeutics Strengthens Leadership Team with the Appointment of Four Industry Leaders to Its Board of Directors
BETHESDA, Md., Feb. 02, 2021 (GLOBE NEWSWIRE) Gain Therapeutics, Inc. (“Gain”) today announced the addition of Dov Goldstein, M.D., Gwen Melincoff, Claude Nicaise, M.D. and Hans Peter Hasler as independent members to its Board of Directors. The new board additions will provide strategic guidance as the company focuses on identifying and optimizing allosteric binding sites that have never before been targeted to unlock new treatment options for difficult-to-treat disorders characterized by protein misfolding. In conjunction with the new additions, Dr. Lorenzo Leoni and Dr. Marianne Bjordal will be stepping down from Board.